UPC Analytics
DEEN
Übersicht · Eingereicht: —

ACT_551308/2023

A SYSTEM COMPRISING A PROSTHETIC VALVE AND A DELIVERY CATHETER

NichtigkeitHauptnichtigkeitsklageParis CDRevocation Action—
ÜbersichtEntscheidungenBegründungZitateDokumenteZeitverlauf
Abdeckung: Teilweise.Begründung teilweise extrahiert — einige Abschnitte können unvollständig sein.
Zusammenfassung in einfacher Sprache

Meril Italy and Meril GmbH/Life Sciences sought revocation of Edwards Lifesciences' EP 3 646 825 (prosthetic heart valve) on inventive step grounds. The Paris Central Division rejected all invalidity attacks against the patent as limited by Edwards' auxiliary request II, which narrowed the claims to require an all-hexagonal cell frame in a specific alloy. The court identified 'Levi' as the closest prior art and found no obvious motivation to combine prior art to arrive at the claimed structure, dismissing the revocation while splitting costs 60/40 because the patent was only saved by in-proceedings amendment.

Angenommene Argumente
Was das Gericht akzeptiert hat — nach Partei.

  • Patent maintained in amended form under auxiliary request II is valid over all asserted invalidity grounds

    BeklagterRechtsgrundlage: Art. 56 EPC

    Hinweis: Edwards successfully defended EP 3 646 825 by limiting the patent to a frame made entirely of hexagonal cells from a specific nickel-cobalt-chromium-molybdenum alloy, which the court found inventive over the prior art.

  • Fontaine's article does not teach that reduced crimping profile derives from all-hexagonal cell geometry

    BeklagterRechtsgrundlage: Art. 56 EPC

    Hinweis: The court found that the Fontaine reference could not be relied on to show the specific technical effect was attributable to the hexagonal geometry, defeating the obviousness attack based on that document.

Zurückgewiesene Argumente
Was das Gericht nicht akzeptiert hat — und warum.

  • Lack of inventive step based on 'Levi' as closest prior art combined with disclosure of hexagonal cells in heart valves

    KlägerRechtsgrundlage: Art. 56 EPC

    Begründung: The court applied the problem-solution approach using 'Levi' as closest prior art and found that the combination did not render the amended claim obvious.

  • All invalidity grounds raised against amended auxiliary request II are well-founded

    KlägerRechtsgrundlage: Art. 56 EPC

    Begründung: The court found all grounds of invalidity unfounded as against the patent in its amended form (auxiliary request II).

Zentrale Rechtsgrundsätze
In der Begründung herangezogene Doktrinen und Regeln.
problem-solution approach (noted as not mandatory under EPC but applied as consistent with outcome)patent limitation during proceedings can defeat revocation actioncost-splitting where revocation dismissed only due to in-proceedings amendment

Weitere Fälle zu diesem Grundsatz ansehen.

Herangezogener Stand der Technik
Zitierte Schriften und die Rolle, die sie gespielt haben.
  • Levi (unspecified publication)Erfindungsmüh-Kombination
  • Fontaine (article)Erfindungsmüh-Kombination
  • WO 2013/012801Hintergrund
  • EP 3 205 309Hintergrund
  • EP 2 731 552Hintergrund
Hinweise zur Anspruchsauslegung

The court construed the amended claim as requiring a prosthetic heart valve frame made up entirely of hexagonal cells (each defined by six struts including two parallel side struts, two lower converging angled struts, and two upper converging angled struts) composed of a specific nickel-cobalt-chromium-molybdenum alloy, mounted on a balloon delivery catheter. The amendment narrowed the original claim by specifying the alloy composition and the all-hexagonal cell requirement.